JPWO2023229032A5 - - Google Patents
Info
- Publication number
- JPWO2023229032A5 JPWO2023229032A5 JP2024523363A JP2024523363A JPWO2023229032A5 JP WO2023229032 A5 JPWO2023229032 A5 JP WO2023229032A5 JP 2024523363 A JP2024523363 A JP 2024523363A JP 2024523363 A JP2024523363 A JP 2024523363A JP WO2023229032 A5 JPWO2023229032 A5 JP WO2023229032A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic
- agent according
- prophylactic agent
- group
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022087166 | 2022-05-27 | ||
| PCT/JP2023/019755 WO2023229032A1 (ja) | 2022-05-27 | 2023-05-26 | 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023229032A1 JPWO2023229032A1 (cg-RX-API-DMAC7.html) | 2023-11-30 |
| JPWO2023229032A5 true JPWO2023229032A5 (cg-RX-API-DMAC7.html) | 2026-06-02 |
Family
ID=88919516
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024523363A Pending JPWO2023229032A1 (cg-RX-API-DMAC7.html) | 2022-05-27 | 2023-05-26 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250352541A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4534100A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2023229032A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403571A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023229032A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4347582A4 (en) | 2021-05-27 | 2025-05-07 | Boundless Bio, Inc. | CHECKPOINT KINASE-1 INHIBITORS AND USES THEREOF |
| EP4626433A1 (en) * | 2022-11-29 | 2025-10-08 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8850801A1 (es) * | 2008-12-17 | 2010-07-27 | Lilly Co Eli | Compuestos útiles para inhibir chk1 |
| JO3145B1 (ar) * | 2010-11-08 | 2017-09-20 | Lilly Co Eli | مركبات مفيدة لتثبيط chk1 |
| GB201402277D0 (en) * | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| CA3013514C (en) * | 2016-02-04 | 2021-11-23 | Pharmaengine, Inc. | 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications |
| CA3135165A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| US12404332B2 (en) * | 2020-03-13 | 2025-09-02 | Research Development Foundation | Methods for diagnosing and treating cancers |
| MX2023006364A (es) * | 2020-11-30 | 2023-06-13 | Sumitomo Pharma Co Ltd | Derivado de 5-heteroaril-1h-pirazol-3-amina. |
-
2023
- 2023-05-26 JP JP2024523363A patent/JPWO2023229032A1/ja active Pending
- 2023-05-26 WO PCT/JP2023/019755 patent/WO2023229032A1/ja not_active Ceased
- 2023-05-26 US US18/867,830 patent/US20250352541A1/en active Pending
- 2023-05-26 EP EP23811904.4A patent/EP4534100A4/en active Pending
- 2023-05-26 CN CN202380043023.8A patent/CN119403571A/zh active Pending